Skip to main content
Premium Trial:

Request an Annual Quote

Downloads and Upgrades: Reactome 44 and ACD/Spectrus DB

Premium

Reactome 44 is available here.

Topics with new or revised information include immune system, cell cycle, extracellular matrix organization, metabolism, signal transduction, transmembrane transport of small molecules, and disease. New pathway illustrations include apoptosis extrinsic pathway, and trafficking and processing of endosomal toll-like receptors.


Advanced Chemistry Development, a cheminformatics software developer, has launched ACD/Spectrus DB, the database at the core of its Spectrus integrated analytical and chemical knowledge management platform.

According to its developers, ACD/Spectrus DB gathers information from multiple analytical instruments and connects chemical structures, reactions, schema, related analytical data, and chemical information, among other features. Users can make customizations to their systems such as automated processing, interpretation, sample tracking, and visualization.


Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.